by A.E. Martinez-Nunez, C.J. Rozell, S. Little, H. Tan, S.L. Schmidt, W.M. Grill, M. Pajic, D. Turner, C. de Hemptinne, A. Machado, A. Becker, R.S. Raike, M. Malekmohammadi, Y. Pathak, L. Himes, D. Greene, L. Krinke, M. Arlotti, L. Rossi, J.T. Robinson, B.H. Bahners, V. Litvak, L. Milosevic, S. Ghatan, F. Schaper, M.D. Fox, N.M. Gregg, C. Kubu, J.J. Giordano, N.G. Cascella, Y.-H. Nho, C. Halpern, H.S. Mayberg, K.S. Choi, H.N. Song, J. Cha, S. Alagapan, N. Dosenbach, E.M. Gordon, J. Ren, H. Liu, L.V. Kalia, D.M. Kusyk, A. Ramirez-Zamora, K.D. Foote, M.S. Okun and J.K. Wong
Abstract:
The Deep Brain Stimulation (DBS) Think Tank XII was held on August 21 st to 23 rd . This year we showcased groundbreaking advancements in neuromodulation technology, focusing heavily on the novel uses of existing technology as well as next-generation technology. Our keynote speaker shared the vision of using neuro artificial intelligence to predict depression using brain electrophysiology. Innovative applications are currently being explored in stroke, disorders of consciousness, and sleep, while established treatments for movement disorders like Parkinson's disease are being refined with adaptive stimulation. Neuromodulation is solidifying its role in treating psychiatric disorders such as depression and obsessive-compulsive disorder, particularly for patients with treatment-resistant symptoms. We estimate that 300,000 leads have been implanted to date for neurologic and neuropsychiatric indications. Magnetoencephalography has provided insights into the post-DBS physiological changes. The field is also critically examining the ethical implications of implants, considering the long-term impacts on clinicians, patients, and manufacturers.
Reference:
Proceedings of the 12th Annual Deep Brain Stimulation Think Tank: Cutting Edge Technology meets Novel ApplicationsA.E. Martinez-Nunez, C.J. Rozell, S. Little, H. Tan, S.L. Schmidt, W.M. Grill, M. Pajic, D. Turner, C. de Hemptinne, A. Machado, A. Becker, R.S. Raike, M. Malekmohammadi, Y. Pathak, L. Himes, D. Greene, L. Krinke, M. Arlotti, L. Rossi, J.T. Robinson, B.H. Bahners, V. Litvak, L. Milosevic, S. Ghatan, F. Schaper, M.D. Fox, N.M. Gregg, C. Kubu, J.J. Giordano, N.G. Cascella, Y.-H. Nho, C. Halpern, H.S. Mayberg, K.S. Choi, H.N. Song, J. Cha, S. Alagapan, N. Dosenbach, E.M. Gordon, J. Ren, H. Liu, L.V. Kalia, D.M. Kusyk, A. Ramirez-Zamora, K.D. Foote, M.S. Okun and J.K. Wong. Frontiers in Human Neuroscience, January 2025.
Bibtex Entry:
@article{wong.25,
author = {Martinez-Nunez, A.E. and Rozell, C.J. and Little, S. and Tan, H. and Schmidt, S.L. and Grill, W.M. and Pajic, M. and Turner, D. and de Hemptinne, C. and Machado, A. and Becker, A. and Raike, R.S. and Malekmohammadi, M. and Pathak, Y. and Himes, L. and Greene, D. and Krinke, L. and Arlotti, M. and Rossi, L. and Robinson, J.T. and Bahners, B.H. and Litvak, V. and Milosevic, L. and Ghatan, S. and Schaper, F. and Fox, M.D. and Gregg, N.M. and Kubu, C. and Giordano, J.J. and Cascella, N.G. and Nho, Y.-H. and Halpern, C. and Mayberg, H.S. and Choi, K.S. and Song, H.N. and Cha, J. and Alagapan, S. and Dosenbach, N. and Gordon, E.M. and Ren, J. and Liu, H. and Kalia, L.V. and Kusyk, D.M. and Ramirez-Zamora, A. and Foote, K.D. and Okun, M.S. and Wong, J.K.},
title = {Proceedings of the 12th Annual Deep Brain Stimulation Think Tank: Cutting Edge Technology meets Novel Applications},
year = 2025,
month = jan,
journal = {Frontiers in Human Neuroscience},
abstract = {The Deep Brain Stimulation (DBS) Think Tank XII was held on August 21 st to 23 rd . This year we showcased groundbreaking advancements in neuromodulation technology, focusing heavily on the novel uses of existing technology as well as next-generation technology. Our keynote speaker shared the vision of using neuro artificial intelligence to predict depression using brain electrophysiology. Innovative applications are currently being explored in stroke, disorders of consciousness, and sleep, while established treatments for movement disorders like Parkinson's disease are being refined with adaptive stimulation. Neuromodulation is solidifying its role in treating psychiatric disorders such as depression and obsessive-compulsive disorder, particularly for patients with treatment-resistant symptoms. We estimate that 300,000 leads have been implanted to date for neurologic and neuropsychiatric indications. Magnetoencephalography has provided insights into the post-DBS physiological changes. The field is also critically examining the ethical implications of implants, considering the long-term impacts on clinicians, patients, and manufacturers.},
url = {https://doi.org/10.3389/fnhum.2025.1544994}
}